Zacks Investment Research
16 Jun 2026, 14:51 UTC · 2h ago
Abbott's CGM Growth Story Stays Intact Despite Q1 Moderation
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
16 Jun 2026, 14:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Abbott management expects its continuous glucose monitoring (CGM) business to return to double-digit growth in the second quarter of 2026. — Positive forward guidance on a core growth driver typically boosts investor confidence and stock price.
+0.40Abbott has secured an agreement with Medtronic's MiniMed to commercialize dual glucose-ketone sensors for integration with smart dosing systems. — Strategic partnerships with major competitors/peers expand market reach and validate new technology.
+0.30Abbott's CGM sales grew 7.5% to $2 billion in Q1 2026, representing a moderation in growth pace. — Deceleration in growth for a key division creates short-term headwinds, though management attributed it to temporary timing issues.
-0.20Continue reading
6 related stories
Search tags
Abbott has expanded its Lingo over-the-counter CGM and app to Android devices. — Increasing the addressable market by expanding OS compatibility is incrementally positive for user adoption.
+0.10Which stocks this story touches
Strong growth in CGM business, new product approvals, and positive management guidance for double-digit growth.
Company is mentioned but no specific news or sentiment is provided in the text snippet.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
59m ago
